Table 1.
Signaling pathways modulated by tDp/Dp32 in oncogenesis-associated activities
| tDp/Dp32 binding partner | Signaling pathways affected | Cell phenotype | Cell type | References |
|---|---|---|---|---|
| ------- | AKT↑* | Resistance to trastuzumab*, tumor growth* | Her2+ breast cancer, gastric cancer | [34, 35, 37, 47] |
| ------- | ------- | Cell migration* | Non-small cell lung cancer; gastric cancer | [12,43] |
| Her2 | AKT↑ | Resistance to trastuzumab | Her2+ cancer | [37] |
| Rlα within PKA | PKA↑ | Resistance to trastuzumab | Her2+ breast cancer | [15] |
| IGF1R | AKT↑, ErbB↑ | High glucose metabolism | Her2+ breast cancer | [16] |
| IKKα | NF-kB2↑ | Cell migration | Non-small cell lung cancer | [12] |
| Unknown | Bcl-2↑ | Anti-apoptosis | Her2+ breast cancer | [35] |
| Unknown | ANGPT2↑, STAT3↑ | Angiogenesis, tumor growth | Gastric cancer | [33] |
| Unknown | Increased interaction between Her1 and Her3; AKT↑ | Resistance to gefitinib (inhibitor of Her1) | Gastric cancer | [46] |
| Unknown | Increased stability of Her1 | Sensitivity to gefitinib, AG1478, and erlotinib (inhibitors of Her1) | Breast cancer | [67] |
| CXC4 | CXC4 increased stability; MT1-MMP/MMP-2 activation | Cell migration | Gastric cancer | [43] |
| SRp20 | CD44E↑ | mRNA splicing | Gastric cancer | [68] |
| Bcl-2 | lnsP3R/Ca2+ | Anti-apoptosis | Leukemia | [69] |
| Unknown | P-catenin↑; Wnt genes↑ | Proliferation | Gastric cancer; esophageal cancer | [70] |
*
Corroborated by independent groups.